 | Up a level |
Mesa, Ruben A., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew 
ORCID: 0000-0003-3644-7093, Mayer, Jiri, Ganly, Peter, Jourdan, Eric, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Cernohous, Paul, Nangalia, Jyoti, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Mead, Adam and Harrison, Claire N.
(2015).
Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
J. Clin. Oncol., 33 (18).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755